FDA Accepts NDA for AstraZeneca's Epanova
September 18, 2013 at 06:24 AM EDT
AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for EpanovaTM, an investigational compound for the treatment for patients with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500mg/dL). The NDA submission for Epanova